Ionis announces positive interim data from partner Roche’s Phase 3 IMAgINATION study in IgA nephropathy (IgAN)

Phase 3positivePositive

AI Analysis

Summary

Ionis announced positive interim data from its partner Roche's Phase 3 IMAgINATION study evaluating a treatment for IgA nephropathy. The positive interim results represent a significant milestone for the development program.

Clinical Trial Data

Phase

Phase 3

Outcome Details

Positive interim data from IMAgINATION study

Importance:7/10

Sentiment:

0.75

Phase 3 dataIgA nephropathypartnershipIonisRoche

Related Companies

$IONS $RHHBY

Read the original article

Published by yahoo_finance on September 23, 2026 5:00 AM

Read Original